QLGN News and Press, Qualigen Therapeutics Inc. From 05/03/22

Qualigen Therapeutics (NASDAQ:QLGN) is acquiring a majority stake in bacterial infection-focused Israeli diagnostics company NanoSynex. Qualigen’s purchase of the controlling interest in NanoSynex will mainly consist of a stock-for-stock acquisition with a controlling shareholder ...

Compan ies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “ Superbugs , ” a Rising Global Health Crisis CARLSBAD, Calif., May 03,...

CARLSBAD, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces...

3 Under $1 Biotech Penny Stocks Flying During Today’s Session Finding biotech penny stocks to buy can be challenging. But, biotech penny stocks are extremely volatile and as a result, they tend to result in either making or losing a lot of money. Some big gainers today alread...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, many of the top trending stocks are part of two distinct categories. Big news out of the pharmaceutical sector has several microcap biotech stocks in the green. Last week, Sunshine Biopharma  (NASDAQ: SBFM ...

Data Highlights In V ivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company...

Qualigen Therapeutics (NASDAQ:QLGN) resumed worldwide distribution and commercial control of FastPack from previous marketing partner Sekisui Diagnostics from April 1, 2022. The sale of FastPack System diagnostic instruments and test kits have exceeded $120M since inception and have...

Company Prepared for Growth and Improved Profitability of its Diagnostics Business CARLSBAD, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences...

Qualigen Therapeutics press release (NASDAQ:QLGN): FY GAAP EPS of -$0.61. Revenue of $5.65M (+98.2% Y/Y). Shares -3.92% PM. For further details see: Qualigen Therapeutics GAAP EPS of -$0.61, revenue of $5.65M

CARLSBAD, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug designation, while also commercializing diagnostics, today ann...